Quick takeaways

• Claims about excess deaths in vaccinated individuals were based on flawed data and incorrect population estimates, as the actual data from the Office for National Statistics showed higher mortality rates in the unvaccinated population.

• The new drug for Alzheimer's, Denanamab, has shown promise in reducing amyloid plaques but the trial results indicate subtle effects and the average difference in cognitive decline between the drug and placebo groups fell below the minimum clinically important difference needed to notice a significant improvement.

Deep dives